-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The conversation delves into various educational resources utilized both by healthcare providers and patients regarding ddalimumab biosimilars.
-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
-
May 10, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 10, 2024Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The dialogue revolves around patient education regarding biosimilar medications, focusing on common questions and concerns raised by patients and healthcare providers.
-
May 3, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 3, 2024Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.
-
May 3, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
May 3, 2024Healthcare providers in inflammatory diseases talk about the role they have on encouraging adalimumab biosimilar use in clinical practice. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The discussion centers on how healthcare professionals can promote the use of adalimumab biosimilars and enhance patient care.
-
Apr 29, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
April 29, 2024Specialists in rheumatology, dermatology and gastrointestinal disease share their clinical experience on initiating or switching their patients on adalimumab biosimilars. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The discussion revolves around experiences initiating patients on biosimilars.
-
Apr 29, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. An expert discusses the safe transition of patients from a reference product to a biosimilar. He emphasizes that although biosimilars may not be identical, they are sufficiently similar in every parameter.
-
Apr 19, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
April 19, 2024Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients. This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The discussion revolves around how to choose the appropriate biosimilar for patients.
-
Apr 19, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The conversation explores strategies to enhance the uptake of biosimilars, focusing on easing administrative burdens and improving patient access and affordability.
-
Apr 12, 2024 | 
hcplive.com | Jamie T. Brogan |Kostas N. Botsoglou |Jordan E. Axelrad |Sophia Z. Humphreys |Peter Lio
This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD. The conversation delves into the role of payers and pharmacy benefit managers (PBMs) in facilitating patient access to biosimilars. PBMs primarily manage formularies, and despite numerous biosimilar launches in the United States, uptake has been relatively low.
